Tags

Type your tag names separated by a space and hit enter

Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone.
J Clin Psychiatry. 2002 May; 63(5):408-13.JC

Abstract

BACKGROUND

This study was conducted to prospectively examine the effect of switching from risperidone to olanzapine on female schizophrenia patients who experienced menstrual disturbances, galactorrhea, and/or sexual dysfunction.

METHOD

Twenty female patients with DSM-IV schizophrenia who were taking risperidone and were suffering from menstrual disturbances, galactorrhea, and/or sexual dysfunction were enrolled. Patients were switched from risperidone to olanzapine over a 2-week period, then treated with olanzapine for 8 additional weeks. The serum prolactin concentrations were examined every 2 weeks. The Positive and Negative Syndrome Scale (PANSS), Abnormal Involuntary Movement Scale (AIMS), Simpson-Angus Scale for Extrapyramidal Symptoms (SAS), and questions from the Dickson-Glazer Sexual Functioning Scale were administered to evaluate efficacy, extrapyramidal side effects, and sexual and reproductive functioning at baseline and the endpoint of 10 weeks.

RESULTS

Serum prolactin levels decreased significantly (p < .01) following the switch from risperidone to olanzapine. Scores of PANSS, AIMS, and SAS at the endpoint were also significantly decreased (p < .01) compared to those of baseline. Patients experienced improvements in menstrual functioning and perceptions of sexual side effects.

CONCLUSION

Olanzapine reversed hyperprolactinemia in risperidone-treated female schizophrenic patients. This was associated with a decrease in amenorrhea, improved cycle regularity, and a decrease in sexual side effects that the women attributed to antipsychotic medication. This study suggests that switching to olanzapine is a safe and effective alternative method for patients with antipsychotic-induced hyperprolactinemia associated sexual and/or reproductive dysfunction. Long-term follow-up studies are warranted, with particular attention to the course of sexual and reproductive dysfunction.

Authors+Show Affiliations

Department of Psychiatry, St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

12019665

Citation

Kim, Kwang-Soo, et al. "Effects of Olanzapine On Prolactin Levels of Female Patients With Schizophrenia Treated With Risperidone." The Journal of Clinical Psychiatry, vol. 63, no. 5, 2002, pp. 408-13.
Kim KS, Pae CU, Chae JH, et al. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. J Clin Psychiatry. 2002;63(5):408-13.
Kim, K. S., Pae, C. U., Chae, J. H., Bahk, W. M., Jun, T. Y., Kim, D. J., & Dickson, R. A. (2002). Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. The Journal of Clinical Psychiatry, 63(5), 408-13.
Kim KS, et al. Effects of Olanzapine On Prolactin Levels of Female Patients With Schizophrenia Treated With Risperidone. J Clin Psychiatry. 2002;63(5):408-13. PubMed PMID: 12019665.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. AU - Kim,Kwang-Soo, AU - Pae,Chi-Un, AU - Chae,Jeong-Ho, AU - Bahk,Won-Myong, AU - Jun,Tae-Youn, AU - Kim,Dai-Jin, AU - Dickson,Ruth A, PY - 2002/5/22/pubmed PY - 2002/6/12/medline PY - 2002/5/22/entrez SP - 408 EP - 13 JF - The Journal of clinical psychiatry JO - J Clin Psychiatry VL - 63 IS - 5 N2 - BACKGROUND: This study was conducted to prospectively examine the effect of switching from risperidone to olanzapine on female schizophrenia patients who experienced menstrual disturbances, galactorrhea, and/or sexual dysfunction. METHOD: Twenty female patients with DSM-IV schizophrenia who were taking risperidone and were suffering from menstrual disturbances, galactorrhea, and/or sexual dysfunction were enrolled. Patients were switched from risperidone to olanzapine over a 2-week period, then treated with olanzapine for 8 additional weeks. The serum prolactin concentrations were examined every 2 weeks. The Positive and Negative Syndrome Scale (PANSS), Abnormal Involuntary Movement Scale (AIMS), Simpson-Angus Scale for Extrapyramidal Symptoms (SAS), and questions from the Dickson-Glazer Sexual Functioning Scale were administered to evaluate efficacy, extrapyramidal side effects, and sexual and reproductive functioning at baseline and the endpoint of 10 weeks. RESULTS: Serum prolactin levels decreased significantly (p < .01) following the switch from risperidone to olanzapine. Scores of PANSS, AIMS, and SAS at the endpoint were also significantly decreased (p < .01) compared to those of baseline. Patients experienced improvements in menstrual functioning and perceptions of sexual side effects. CONCLUSION: Olanzapine reversed hyperprolactinemia in risperidone-treated female schizophrenic patients. This was associated with a decrease in amenorrhea, improved cycle regularity, and a decrease in sexual side effects that the women attributed to antipsychotic medication. This study suggests that switching to olanzapine is a safe and effective alternative method for patients with antipsychotic-induced hyperprolactinemia associated sexual and/or reproductive dysfunction. Long-term follow-up studies are warranted, with particular attention to the course of sexual and reproductive dysfunction. SN - 0160-6689 UR - https://www.unboundmedicine.com/medline/citation/12019665/Effects_of_olanzapine_on_prolactin_levels_of_female_patients_with_schizophrenia_treated_with_risperidone_ L2 - http://www.psychiatrist.com/jcp/article/pages/2002/v63n05/v63n0506.aspx DB - PRIME DP - Unbound Medicine ER -